España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Celldex Therapeutics
CLDX
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$43.86
0
0.00%
At close: Jul 25, 5:01 PM EDT
$43.86
0
0.00%
After Hours: 5:01 PM EDT
15 minutes delayed
Get Report
Comment
Celldex Therapeutics (CLDX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Celldex Therapeutics (NASDAQ:CLDX) Stock
Celldex Therapeutics Stock (NASDAQ: CLDX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, July 16, 2024
Analyst Expectations For Celldex Therapeutics's Future
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Celldex Therapeutics Begins Global Phase 3 Pr...
Benzinga Newsdesk
Tuesday, June 18, 2024
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Tuesday, June 11, 2024
Wolfe Research Initiates Coverage On Celldex ...
Benzinga Newsdesk
Monday, June 03, 2024
Analyst Expectations For Celldex Therapeutics's Future
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Sunday, June 02, 2024
Celldex Therapeutics Reported Data Showing Barzolvolimab Improves Angioedema At 12 Weeks In Phase 2 Study For Chronic Spontaneous Urticaria
Charles Gross
Wednesday, May 15, 2024
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Celldex Doses First Patient In Phase 2 Study ...
Benzinga Newsdesk
Tuesday, May 07, 2024
Unveiling 4 Analyst Insights On Celldex Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Monday, May 06, 2024
Celldex Therapeutics Q1 EPS $(0.56) Beats $(0...
Benzinga Newsdesk
Wednesday, April 17, 2024
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Celldex Completes Enrollment In Phase 2 Study...
Benzinga Newsdesk
Friday, March 22, 2024
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Friday, March 15, 2024
Market-Moving News for March 15th
Benzinga Newsdesk
Friday, March 01, 2024
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Reported Earlier, Celldex Therapeutics Prices...
Benzinga Newsdesk
Wednesday, February 28, 2024
Celldex Therapeutics Proposes To Offer And Se...
Benzinga Newsdesk
Tuesday, February 27, 2024
Guggenheim Maintains Buy on Celldex Therapeut...
Benzinga Newsdesk
Monday, February 26, 2024
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
Celldex Therapeutics shares are trading highe...
Benzinga Newsdesk
Celldex Therapeutics: Q4 Earnings Insights
Benzinga Insights
Celldex Therapeutics Entered Deal To Sell Sha...
Benzinga Newsdesk
Celldex Therapeutics Q4 EPS $(0.83) Misses $(...
Benzinga Newsdesk
Saturday, February 24, 2024
Celldex Therapeutics Earlier Announced Phase 2 Results For Barzolvolimab In Chronic Spontaneous Urticaria Patients, Meeting Primary and Secondary Endpoints
Charles Gross
Monday, February 05, 2024
Celldex Announces Upcoming Presentation Of Ba...
Benzinga Newsdesk
Wednesday, December 20, 2023
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
Benzinga Insights
TD Cowen Initiates Coverage On Celldex Therap...
Benzinga Newsdesk
Top 4 Health Care Stocks That May Crash This Month
Avi Kapoor
Friday, November 10, 2023
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
Benzinga Insights
Wells Fargo Upgrades Celldex Therapeutics to ...
Benzinga Newsdesk
Wednesday, November 08, 2023
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
Henry Khederian
Celldex Therapeutics shares are trading lower...
Benzinga Newsdesk
Celldex Therapeutics Prices Public Offering o...
Benzinga Newsdesk
Tuesday, November 07, 2023
Celldex Therapeutics Announces Proposed Publi...
Benzinga Newsdesk
Monday, November 06, 2023
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
HC Wainwright & Co. Maintains Buy on Celldex ...
Benzinga Newsdesk
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
Vandana Singh
Market-Moving News for November 6th
Benzinga Newsdesk
Celldex Therapeutics shares are trading highe...
Luke J Jacobi
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Celldex Therapeutics' Topline Results From It...
Benzinga Newsdesk
Reported Earlier, Celldex Therapeutics Announ...
Benzinga Newsdesk
Friday, November 03, 2023
Celldex Therapeutics Inc Files For Mixed Shel...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Cel...
Benzinga Newsdesk
Celldex Therapeutics shares are trading highe...
Benzinga Newsdesk
Thursday, November 02, 2023
Celldex Therapeutics Q3 EPS $(0.81) Misses $(...
Benzinga Newsdesk
Celldex Therapeutics Unusual Options Activity
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch